Literature DB >> 16953226

Telomeric aggregates and end-to-end chromosomal fusions require myc box II.

A Caporali1, L Wark, B J Vermolen, Y Garini, S Mai.   

Abstract

Telomeres of tumor cells form telomeric aggregates (TAs) within the three-dimensional (3D) interphase nucleus. Some of these TAs represent end-to-end chromosomal fusions and may subsequently initiate breakage-bridge-fusion cycles. Wild-type (wt) and myc box II mutant (mt) Myc induce different types of genomic instability when conditionally expressed in mouse proB cells (Ba/F3). Only wt Myc overexpressing Ba/F3 cells are capable of tumor formation in severe combined immunodeficient mice. In this study, we investigated whether telomere dysfunction leading to TA formation is linked to the genetic changes that permit wt c-Myc-dependent transformation of Ba/F3 cells. To this end, we examined the 3D organization of telomeres after the deregulated expression of deletion myc boxII mutant (Delta106) or wt Myc. Delta106-Myc overexpression did not induce TAs, whereas wt-Myc deregulation did. Instead, Delta106-Myc remodelled the 3D telomeric organization such that telomeres aligned in the center of the 3D interphase nucleus forming a telomeric disk owing to a Delta106-induced G1/S cell cycle arrest. In contrast, wt-Myc overexpression led to distorted telomere distribution and TA formation. Analysis of chromosomal alterations using spectral karyotyping confirmed Delta106-Myc and wt-Myc-associated genomic instability. A significant number of chromosomal end-to-end fusions indicative of telomere dysfunction were noted in wt-Myc-expressing cells only. This study suggests that TAs may play a fundamental role in Myc-induced tumorigenesis and provides a novel way to dissect tumor initiation.

Entities:  

Mesh:

Year:  2006        PMID: 16953226     DOI: 10.1038/sj.onc.1209928

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  c-Myc-dependent formation of Robertsonian translocation chromosomes in mouse cells.

Authors:  Amanda Guffei; Zelda Lichtensztejn; Amanda Gonçalves Dos Santos Silva; Sherif F Louis; Andrea Caporali; Sabine Mai
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

2.  Three-dimensional telomere dynamics in follicular thyroid cancer.

Authors:  Landon Wark; Adrian Danescu; Suchitra Natarajan; Xuguang Zhu; Sheue-yann Cheng; Sabine Hombach-Klonisch; Sabine Mai; Thomas Klonisch
Journal:  Thyroid       Date:  2013-09-04       Impact factor: 6.568

3.  Telomere-centromere-driven genomic instability contributes to karyotype evolution in a mouse model of melanoma.

Authors:  Amanda Gonçalves Dos Santos Silva; Herbert Alexander Graves; Amanda Guffei; Tatiana Iervolino Ricca; Renato Arruda Mortara; Miriam Galvonas Jasiulionis; Sabine Mai
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

Review 4.  c-MYC-induced genomic instability.

Authors:  Alexandra Kuzyk; Sabine Mai
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

5.  Selected telomere length changes and aberrant three-dimensional nuclear telomere organization during fast-onset mouse plasmacytomas.

Authors:  Alexandra Kuzyk; Sabine Mai
Journal:  Neoplasia       Date:  2012-04       Impact factor: 5.715

6.  3D nuclear organization and genomic instability in cancer.

Authors:  Sabine Mai
Journal:  BMC Proc       Date:  2013-04-04

7.  Three-dimensional telomere profiles in papillary thyroid cancer variants: A pilot study.

Authors:  Aline Rangel-Pozzo; Tinuccia Dettori; Daniela Virginia Frau; Federica Etzi; John Gartner; Garbor Fisher; Roberta Vanni; Sabine Mai; Paola Caria
Journal:  Bosn J Basic Med Sci       Date:  2022-06-01       Impact factor: 3.759

8.  Distinct nuclear orientation patterns for mouse chromosome 11 in normal B lymphocytes.

Authors:  Ann-Kristin Schmälter; Alexandra Kuzyk; Christiaan H Righolt; Michaela Neusser; Ortrud K Steinlein; Stefan Müller; Sabine Mai
Journal:  BMC Cell Biol       Date:  2014-06-12       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.